Posted by Michael Wonder on 29 Apr 2024
Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER positive breast cancer
29 April 2024 - Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50% versus Faslodex standard of care in a biomarker-altered population
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union for the treatment of adult patients with estrogen receptor positive, HER2 negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations following recurrence or progression on or after an endocrine-based regimen.
